Dimensional Fund Advisors’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-832,761
| Closed | -$8.3M | – | 3312 |
|
|
2025
Q2 | $8.3M | Sell |
832,761
-348,493
| -30% | -$2.81M | ﹤0.01% | 2339 |
|
|
2025
Q1 | $7.05M | Sell |
1,181,254
-28,826
| -2% | -$212K | ﹤0.01% | 2387 |
|
|
2024
Q4 | $9.29M | Buy |
1,210,080
+163,880
| +16% | +$1.41M | ﹤0.01% | 2341 |
|
|
2024
Q3 | $10.7M | Buy |
1,046,200
+137,871
| +15% | +$2.1M | ﹤0.01% | 2276 |
|
|
2024
Q2 | $13.5M | Buy |
908,329
+117,159
| +15% | +$1.68M | ﹤0.01% | 2133 |
|
|
2024
Q1 | $10.8M | Buy |
791,170
+18,027
| +2% | +$196K | ﹤0.01% | 2279 |
|
|
2023
Q4 | $8.47M | Buy |
773,143
+72,190
| +10% | +$716K | ﹤0.01% | 2385 |
|
|
2023
Q3 | $7.68M | Buy |
700,953
+122,304
| +21% | +$1.56M | ﹤0.01% | 2378 |
|
|
2023
Q2 | $7.66M | Buy |
578,649
+163,043
| +39% | +$2.32M | ﹤0.01% | 2369 |
|
|
2023
Q1 | $5.66M | Buy |
415,606
+250,455
| +152% | +$4.49M | ﹤0.01% | 2445 |
|
|
2022
Q4 | $3.23K | Buy |
165,151
+147,277
| +824% | +$2.88M | ﹤0.01% | 2575 |
|
|
2022
Q3 | $340K | Hold |
17,874
| – | – | ﹤0.01% | 3132 |
|
|
2022
Q2 | $368K | Sell |
17,874
-110,216
| -86% | -$2.62M | ﹤0.01% | 3134 |
|
|
2022
Q1 | $4.12M | Hold |
128,090
| – | – | ﹤0.01% | 2596 |
|
|
2021
Q4 | $5.96M | Buy |
128,090
+79,441
| +163% | +$2.64M | ﹤0.01% | 2506 |
|
|
2021
Q3 | $1.31M | Buy |
+48,649
| New | +$1.27M | ﹤0.01% | 2979 |
|
Other funds holding ITOS
Dimensional Fund Advisors's ITOS Position: Q3 2025 in Review
Dimensional Fund Advisors sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 832,761 shares — an estimated $8.3M sold.
Dimensional Fund Advisors first reported a position in ITOS in Q3 2021 and held it in 16 quarters. The position peaked at $13.5M in Q2 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Dimensional Fund Advisors reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Dimensional Fund Advisors sold 832,761 iTeos Therapeutics shares in Q3 2025, an estimated $8.3M.
- Dimensional Fund Advisors first reported a position in iTeos Therapeutics in Q3 2021 and held it in 16 quarters.
- Dimensional Fund Advisors's iTeos Therapeutics position peaked at $13.5M in Q2 2024.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Dimensional Fund Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.